Aurobindo Pharma gets Canada nod for terbinafine
MUMBAI, Dec 24 (Reuters) - Drug maker Aurobindo Pharma Ltd (ARBN.BO: Quote, Profile, Research) said on Wednesday it received the Canadian regulatory approval to sell terbinafine hydrochloride tablets in multiple strengths.
The drug is the generic equivalent of Novartis' (NOVN.VX: Quote, Profile, Research) Lamisil indicated for the treatment of fungal infections in the skin and nails, the company said in a statement. (Reporting by Bharghavi Nagaraju; Editing by Prem Udayabhanu)
© Thomson Reuters 2009 All rights reserved
UK joins G20 push for world levy on banks
Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change. Full Article | Full Coverage
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article
India
US
UK
